Journal
PHARMACEUTICALS
Volume 15, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ph15121494
Keywords
diabetic nephropathies; drug delivery systems; kidney tubules; proximal; molecular targeted therapy; diabetes mellitus
Categories
Funding
- [Hunan Provincial Natural Science Foundation for Outstanding Youth] [2022JJ10093]
- [Scientific Research Fund of Hunan Provincial Health Commission] [B202303056777]
- Natural Science Foundation of China [81870500]
- Second Xiangya Hospital of Central South University
Ask authors/readers for more resources
Diabetic kidney disease is a major cause of end-stage kidney disease worldwide, and new drug delivery strategies and targeted therapies are urgently needed.
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) worldwide. A significant number of drugs have been clinically investigated for the treatment of DKD. However, a large proportion of patients still develop end-stage kidney disease unstoppably. As a result, new effective therapies are urgently needed to slow down the progression of DKD. Recently, there is increasing evidence that targeted drug delivery strategies such as large molecule carriers, small molecule prodrugs, and nanoparticles can improve drug efficacy and reduce adverse side effects. There is no doubt that targeted drug delivery strategies have epoch-making significance and great application prospects for the treatment of DKD. In addition, the proximal tubule plays a very critical role in the progression of DKD. Consequently, the purpose of this paper is to summarize the current understanding of proximal tubule cell-targeted therapy, screen for optimal targeting strategies, and find new therapeutic approaches for the treatment of DKD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available